What is the projected market valuation of the Pediatric Vaccines Market by 2035?

The Pediatric Vaccines Market is projected to reach a valuation of 54.25 USD Billion by 2035. Read More

What was the market valuation of the Pediatric Vaccines Market in 2024?

In 2024, the Pediatric Vaccines Market was valued at 19.2 USD Billion. Read More

What is the expected CAGR for the Pediatric Vaccines Market during the forecast period 2025 - 2035?

The expected CAGR for the Pediatric Vaccines Market during the forecast period 2025 - 2035 is 9.9%. Read More

Which companies are considered key players in the Pediatric Vaccines Market?

Key players in the Pediatric Vaccines Market include Pfizer, Merck & Co., GlaxoSmithKline, Sanofi, Moderna, Baxter International, Novartis, Bristol-Myers Squibb, and AstraZeneca. Read More

What are the different types of vaccines in the Pediatric Vaccines Market and their valuations?

The market includes Inactivated Vaccines valued at 16.25 USD Billion, Live Attenuated Vaccines at 18.75 USD Billion, Subunit Vaccines at 12.0 USD Billion, and Toxoid Vaccines at 7.25 USD Billion. Read More

How is the Pediatric Vaccines Market segmented by administration route?

By administration route, the market segments include Intramuscular at 21.25 USD Billion, Subcutaneous at 13.5 USD Billion, Oral at 10.75 USD Billion, and Intranasal at 8.75 USD Billion. Read More

What age groups are targeted in the Pediatric Vaccines Market?

The market targets Infants valued at 16.0 USD Billion, Toddlers at 13.5 USD Billion, Preschoolers at 11.5 USD Billion, and School Age children at 13.25 USD Billion. Read More

What diseases are primarily targeted by vaccines in the Pediatric Vaccines Market?

The market targets Viral Infections valued at 16.05 USD Billion, Bacterial Infections at 17.25 USD Billion, Parasitic Infections at 11.75 USD Billion, and Autoimmune Diseases at 7.2 USD Billion. Read More

What immunization schedules are included in the Pediatric Vaccines Market?

The market includes Routine Immunization valued at 27.0 USD Billion, Catch-up Immunization at 13.5 USD Billion, Travel Vaccination at 6.75 USD Billion, and Special Circumstances at 6.0 USD Billion. Read More

How does the Pediatric Vaccines Market's growth potential appear in the coming years?

The growth potential of the Pediatric Vaccines Market appears robust, with a projected increase in valuation and a CAGR of 9.9% from 2025 to 2035. Read More

Pediatric Vaccines Market

ID: MRFR/Pharma/4323-HCR

95 Pages

Vikita Thakur

Last Updated: April 15, 2026

Pediatric Vaccines Market Research Report: Size, Share, Trend Analysis By Vaccine Type (Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Conjugate Vaccines), By Administration Route (Intramuscular, Subcutaneous, Oral, Nasal), By Age Group (Infants, Children, Adolescents), By Disease Target (Viral Infections, Bacterial Infections, Parasitic Infections) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Methodology Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Vaccine Type (USD Billion) | |
  1. 4.1.1 Inactivated Vaccine | |
  2. 4.1.2 Live Attenuated Vaccine | |
  3. 4.1.3 Subunit Vaccine | |
  4. 4.1.4 Toxoid Vaccine |
2. 4.2 Healthcare, BY Administration Route (USD Billion) | |
  1. 4.2.1 Intramuscular | |
  2. 4.2.2 Subcutaneous | |
  3. 4.2.3 Oral | |
  4. 4.2.4 Intranasal |
3. 4.3 Healthcare, BY Age Group (USD Billion) | |
  1. 4.3.1 Infants | |
  2. 4.3.2 Toddlers | |
  3. 4.3.3 Preschoolers | |
  4. 4.3.4 School Age |
4. 4.4 Healthcare, BY Disease Target (USD Billion) | |
  1. 4.4.1 Viral Infections | |
  2. 4.4.2 Bacterial Infections | |
  3. 4.4.3 Parasitic Infections | |
  4. 4.4.4 Autoimmune Diseases |
5. 4.5 Healthcare, BY Immunization Schedule (USD Billion) | |
  1. 4.5.1 Routine Immunization | |
  2. 4.5.2 Catch-up Immunization | |
  3. 4.5.3 Travel Vaccination | |
  4. 4.5.4 Special Circumstances |
6. 4.6 Healthcare, BY Region (USD Billion) | |
  1. 4.6.1 North America | | |
    1. 4.6.1.1 US | | |
    2. 4.6.1.2 Canada | |
  2. 4.6.2 Europe | | |
    1. 4.6.2.1 Germany | | |
    2. 4.6.2.2 UK | | |
    3. 4.6.2.3 France | | |
    4. 4.6.2.4 Russia | | |
    5. 4.6.2.5 Italy | | |
    6. 4.6.2.6 Spain | | |
    7. 4.6.2.7 Rest of Europe | |
  3. 4.6.3 APAC | | |
    1. 4.6.3.1 China | | |
    2. 4.6.3.2 India | | |
    3. 4.6.3.3 Japan | | |
    4. 4.6.3.4 South Korea | | |
    5. 4.6.3.5 Malaysia | | |
    6. 4.6.3.6 Thailand | | |
    7. 4.6.3.7 Indonesia | | |
    8. 4.6.3.8 Rest of APAC | |
  4. 4.6.4 South America | | |
    1. 4.6.4.1 Brazil | | |
    2. 4.6.4.2 Mexico | | |
    3. 4.6.4.3 Argentina | | |
    4. 4.6.4.4 Rest of South America | |
  5. 4.6.5 MEA | | |
    1. 4.6.5.1 GCC Countries | | |
    2. 4.6.5.2 South Africa | | |
    3. 4.6.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Pfizer (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Merck & Co. (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 GlaxoSmithKline (GB) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Sanofi (FR) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Moderna (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Baxter International (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Novartis (CH) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Bristol-Myers Squibb (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 AstraZeneca (GB) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY VACCINE TYPE |
7. 6.4 US MARKET ANALYSIS BY ADMINISTRATION ROUTE |
8. 6.5 US MARKET ANALYSIS BY AGE GROUP |
9. 6.6 US MARKET ANALYSIS BY DISEASE TARGET |
10. 6.7 US MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
11. 6.8 CANADA MARKET ANALYSIS BY VACCINE TYPE |
12. 6.9 CANADA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
13. 6.10 CANADA MARKET ANALYSIS BY AGE GROUP |
14. 6.11 CANADA MARKET ANALYSIS BY DISEASE TARGET |
15. 6.12 CANADA MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
16. 6.13 EUROPE MARKET ANALYSIS |
17. 6.14 GERMANY MARKET ANALYSIS BY VACCINE TYPE |
18. 6.15 GERMANY MARKET ANALYSIS BY ADMINISTRATION ROUTE |
19. 6.16 GERMANY MARKET ANALYSIS BY AGE GROUP |
20. 6.17 GERMANY MARKET ANALYSIS BY DISEASE TARGET |
21. 6.18 GERMANY MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
22. 6.19 UK MARKET ANALYSIS BY VACCINE TYPE |
23. 6.20 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE |
24. 6.21 UK MARKET ANALYSIS BY AGE GROUP |
25. 6.22 UK MARKET ANALYSIS BY DISEASE TARGET |
26. 6.23 UK MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
27. 6.24 FRANCE MARKET ANALYSIS BY VACCINE TYPE |
28. 6.25 FRANCE MARKET ANALYSIS BY ADMINISTRATION ROUTE |
29. 6.26 FRANCE MARKET ANALYSIS BY AGE GROUP |
30. 6.27 FRANCE MARKET ANALYSIS BY DISEASE TARGET |
31. 6.28 FRANCE MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
32. 6.29 RUSSIA MARKET ANALYSIS BY VACCINE TYPE |
33. 6.30 RUSSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
34. 6.31 RUSSIA MARKET ANALYSIS BY AGE GROUP |
35. 6.32 RUSSIA MARKET ANALYSIS BY DISEASE TARGET |
36. 6.33 RUSSIA MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
37. 6.34 ITALY MARKET ANALYSIS BY VACCINE TYPE |
38. 6.35 ITALY MARKET ANALYSIS BY ADMINISTRATION ROUTE |
39. 6.36 ITALY MARKET ANALYSIS BY AGE GROUP |
40. 6.37 ITALY MARKET ANALYSIS BY DISEASE TARGET |
41. 6.38 ITALY MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
42. 6.39 SPAIN MARKET ANALYSIS BY VACCINE TYPE |
43. 6.40 SPAIN MARKET ANALYSIS BY ADMINISTRATION ROUTE |
44. 6.41 SPAIN MARKET ANALYSIS BY AGE GROUP |
45. 6.42 SPAIN MARKET ANALYSIS BY DISEASE TARGET |
46. 6.43 SPAIN MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
47. 6.44 REST OF EUROPE MARKET ANALYSIS BY VACCINE TYPE |
48. 6.45 REST OF EUROPE MARKET ANALYSIS BY ADMINISTRATION ROUTE |
49. 6.46 REST OF EUROPE MARKET ANALYSIS BY AGE GROUP |
50. 6.47 REST OF EUROPE MARKET ANALYSIS BY DISEASE TARGET |
51. 6.48 REST OF EUROPE MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
52. 6.49 APAC MARKET ANALYSIS |
53. 6.50 CHINA MARKET ANALYSIS BY VACCINE TYPE |
54. 6.51 CHINA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
55. 6.52 CHINA MARKET ANALYSIS BY AGE GROUP |
56. 6.53 CHINA MARKET ANALYSIS BY DISEASE TARGET |
57. 6.54 CHINA MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
58. 6.55 INDIA MARKET ANALYSIS BY VACCINE TYPE |
59. 6.56 INDIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
60. 6.57 INDIA MARKET ANALYSIS BY AGE GROUP |
61. 6.58 INDIA MARKET ANALYSIS BY DISEASE TARGET |
62. 6.59 INDIA MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
63. 6.60 JAPAN MARKET ANALYSIS BY VACCINE TYPE |
64. 6.61 JAPAN MARKET ANALYSIS BY ADMINISTRATION ROUTE |
65. 6.62 JAPAN MARKET ANALYSIS BY AGE GROUP |
66. 6.63 JAPAN MARKET ANALYSIS BY DISEASE TARGET |
67. 6.64 JAPAN MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
68. 6.65 SOUTH KOREA MARKET ANALYSIS BY VACCINE TYPE |
69. 6.66 SOUTH KOREA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
70. 6.67 SOUTH KOREA MARKET ANALYSIS BY AGE GROUP |
71. 6.68 SOUTH KOREA MARKET ANALYSIS BY DISEASE TARGET |
72. 6.69 SOUTH KOREA MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
73. 6.70 MALAYSIA MARKET ANALYSIS BY VACCINE TYPE |
74. 6.71 MALAYSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
75. 6.72 MALAYSIA MARKET ANALYSIS BY AGE GROUP |
76. 6.73 MALAYSIA MARKET ANALYSIS BY DISEASE TARGET |
77. 6.74 MALAYSIA MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
78. 6.75 THAILAND MARKET ANALYSIS BY VACCINE TYPE |
79. 6.76 THAILAND MARKET ANALYSIS BY ADMINISTRATION ROUTE |
80. 6.77 THAILAND MARKET ANALYSIS BY AGE GROUP |
81. 6.78 THAILAND MARKET ANALYSIS BY DISEASE TARGET |
82. 6.79 THAILAND MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
83. 6.80 INDONESIA MARKET ANALYSIS BY VACCINE TYPE |
84. 6.81 INDONESIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
85. 6.82 INDONESIA MARKET ANALYSIS BY AGE GROUP |
86. 6.83 INDONESIA MARKET ANALYSIS BY DISEASE TARGET |
87. 6.84 INDONESIA MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
88. 6.85 REST OF APAC MARKET ANALYSIS BY VACCINE TYPE |
89. 6.86 REST OF APAC MARKET ANALYSIS BY ADMINISTRATION ROUTE |
90. 6.87 REST OF APAC MARKET ANALYSIS BY AGE GROUP |
91. 6.88 REST OF APAC MARKET ANALYSIS BY DISEASE TARGET |
92. 6.89 REST OF APAC MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
93. 6.90 SOUTH AMERICA MARKET ANALYSIS |
94. 6.91 BRAZIL MARKET ANALYSIS BY VACCINE TYPE |
95. 6.92 BRAZIL MARKET ANALYSIS BY ADMINISTRATION ROUTE |
96. 6.93 BRAZIL MARKET ANALYSIS BY AGE GROUP |
97. 6.94 BRAZIL MARKET ANALYSIS BY DISEASE TARGET |
98. 6.95 BRAZIL MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
99. 6.96 MEXICO MARKET ANALYSIS BY VACCINE TYPE |
100. 6.97 MEXICO MARKET ANALYSIS BY ADMINISTRATION ROUTE |
101. 6.98 MEXICO MARKET ANALYSIS BY AGE GROUP |
102. 6.99 MEXICO MARKET ANALYSIS BY DISEASE TARGET |
103. 6.100 MEXICO MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
104. 6.101 ARGENTINA MARKET ANALYSIS BY VACCINE TYPE |
105. 6.102 ARGENTINA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
106. 6.103 ARGENTINA MARKET ANALYSIS BY AGE GROUP |
107. 6.104 ARGENTINA MARKET ANALYSIS BY DISEASE TARGET |
108. 6.105 ARGENTINA MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
109. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY VACCINE TYPE |
110. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
111. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY AGE GROUP |
112. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE TARGET |
113. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
114. 6.111 MEA MARKET ANALYSIS |
115. 6.112 GCC COUNTRIES MARKET ANALYSIS BY VACCINE TYPE |
116. 6.113 GCC COUNTRIES MARKET ANALYSIS BY ADMINISTRATION ROUTE |
117. 6.114 GCC COUNTRIES MARKET ANALYSIS BY AGE GROUP |
118. 6.115 GCC COUNTRIES MARKET ANALYSIS BY DISEASE TARGET |
119. 6.116 GCC COUNTRIES MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
120. 6.117 SOUTH AFRICA MARKET ANALYSIS BY VACCINE TYPE |
121. 6.118 SOUTH AFRICA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
122. 6.119 SOUTH AFRICA MARKET ANALYSIS BY AGE GROUP |
123. 6.120 SOUTH AFRICA MARKET ANALYSIS BY DISEASE TARGET |
124. 6.121 SOUTH AFRICA MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
125. 6.122 REST OF MEA MARKET ANALYSIS BY VACCINE TYPE |
126. 6.123 REST OF MEA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
127. 6.124 REST OF MEA MARKET ANALYSIS BY AGE GROUP |
128. 6.125 REST OF MEA MARKET ANALYSIS BY DISEASE TARGET |
129. 6.126 REST OF MEA MARKET ANALYSIS BY IMMUNIZATION SCHEDULE |
130. 6.127 KEY BUYING CRITERIA OF HEALTHCARE |
131. 6.128 RESEARCH PROCESS OF MRFR |
132. 6.129 DRO ANALYSIS OF HEALTHCARE |
133. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
134. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
135. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE |
136. 6.133 HEALTHCARE, BY VACCINE TYPE, 2024 (% SHARE) |
137. 6.134 HEALTHCARE, BY VACCINE TYPE, 2024 TO 2035 (USD Billion) |
138. 6.135 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE) |
139. 6.136 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion) |
140. 6.137 HEALTHCARE, BY AGE GROUP, 2024 (% SHARE) |
141. 6.138 HEALTHCARE, BY AGE GROUP, 2024 TO 2035 (USD Billion) |
142. 6.139 HEALTHCARE, BY DISEASE TARGET, 2024 (% SHARE) |
143. 6.140 HEALTHCARE, BY DISEASE TARGET, 2024 TO 2035 (USD Billion) |
144. 6.141 HEALTHCARE, BY IMMUNIZATION SCHEDULE, 2024 (% SHARE) |
145. 6.142 HEALTHCARE, BY IMMUNIZATION SCHEDULE, 2024 TO 2035 (USD Billion) |
146. 6.143 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
147. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
148. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY AGE GROUP, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY DISEASE TARGET, 2025-2035 (USD Billion) | |
  5. 7.2.5 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) |
149. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY AGE GROUP, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY DISEASE TARGET, 2025-2035 (USD Billion) | |
  5. 7.3.5 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) |
150. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY AGE GROUP, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY DISEASE TARGET, 2025-2035 (USD Billion) | |
  5. 7.4.5 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) |
151. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY AGE GROUP, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY DISEASE TARGET, 2025-2035 (USD Billion) | |
  5. 7.5.5 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) |
152. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY AGE GROUP, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY DISEASE TARGET, 2025-2035 (USD Billion) | |
  5. 7.6.5 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) |
153. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY AGE GROUP, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY DISEASE TARGET, 2025-2035 (USD Billion) | |
  5. 7.7.5 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) |
154. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY AGE GROUP, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY DISEASE TARGET, 2025-2035 (USD Billion) | |
  5. 7.8.5 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) |
155. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY AGE GROUP, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY DISEASE TARGET, 2025-2035 (USD Billion) | |
  5. 7.9.5 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) |
156. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY AGE GROUP, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY DISEASE TARGET, 2025-2035 (USD Billion) | |
  5. 7.10.5 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) |
157. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY AGE GROUP, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY DISEASE TARGET, 2025-2035 (USD Billion) | |
  5. 7.11.5 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) |
158. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY AGE GROUP, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY DISEASE TARGET, 2025-2035 (USD Billion) | |
  5. 7.12.5 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) |
159. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY AGE GROUP, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY DISEASE TARGET, 2025-2035 (USD Billion) | |
  5. 7.13.5 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) |
160. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY AGE GROUP, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY DISEASE TARGET, 2025-2035 (USD Billion) | |
  5. 7.14.5 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) |
161. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY AGE GROUP, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY DISEASE TARGET, 2025-2035 (USD Billion) | |
  5. 7.15.5 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) |
162. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY AGE GROUP, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY DISEASE TARGET, 2025-2035 (USD Billion) | |
  5. 7.16.5 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) |
163. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY AGE GROUP, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY DISEASE TARGET, 2025-2035 (USD Billion) | |
  5. 7.17.5 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) |
164. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY AGE GROUP, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY DISEASE TARGET, 2025-2035 (USD Billion) | |
  5. 7.18.5 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) |
165. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY AGE GROUP, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY DISEASE TARGET, 2025-2035 (USD Billion) | |
  5. 7.19.5 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) |
166. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY AGE GROUP, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY DISEASE TARGET, 2025-2035 (USD Billion) | |
  5. 7.20.5 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) |
167. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY AGE GROUP, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY DISEASE TARGET, 2025-2035 (USD Billion) | |
  5. 7.21.5 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) |
168. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY AGE GROUP, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY DISEASE TARGET, 2025-2035 (USD Billion) | |
  5. 7.22.5 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) |
169. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY AGE GROUP, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY DISEASE TARGET, 2025-2035 (USD Billion) | |
  5. 7.23.5 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) |
170. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY AGE GROUP, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY DISEASE TARGET, 2025-2035 (USD Billion) | |
  5. 7.24.5 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) |
171. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY AGE GROUP, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY DISEASE TARGET, 2025-2035 (USD Billion) | |
  5. 7.25.5 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) |
172. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY AGE GROUP, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY DISEASE TARGET, 2025-2035 (USD Billion) | |
  5. 7.26.5 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) |
173. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY AGE GROUP, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY DISEASE TARGET, 2025-2035 (USD Billion) | |
  5. 7.27.5 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) |
174. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY AGE GROUP, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY DISEASE TARGET, 2025-2035 (USD Billion) | |
  5. 7.28.5 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) |
175. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY AGE GROUP, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY DISEASE TARGET, 2025-2035 (USD Billion) | |
  5. 7.29.5 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) |
176. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY VACCINE TYPE, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY AGE GROUP, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY DISEASE TARGET, 2025-2035 (USD Billion) | |
  5. 7.30.5 BY IMMUNIZATION SCHEDULE, 2025-2035 (USD Billion) |
177. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
178. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Vaccine Type (USD Billion, 2025-2035)

Inactivated Vaccine
Live Attenuated Vaccine
Subunit Vaccine
Toxoid Vaccine

Healthcare By Administration Route (USD Billion, 2025-2035)

Intramuscular
Subcutaneous
Oral
Intranasal

Healthcare By Age Group (USD Billion, 2025-2035)

Infants
Toddlers
Preschoolers
School Age

Healthcare By Disease Target (USD Billion, 2025-2035)

Viral Infections
Bacterial Infections
Parasitic Infections
Autoimmune Diseases

Healthcare By Immunization Schedule (USD Billion, 2025-2035)

Routine Immunization
Catch-up Immunization
Travel Vaccination
Special Circumstances

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓